Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Multitarget PPARĪ³ agonists as innovative modulators of the metabolic syndrome.

Ammazzalorso A, Maccallini C, Amoia P, Amoroso R.

Eur J Med Chem. 2019 Jul 1;173:261-273. doi: 10.1016/j.ejmech.2019.04.030. Epub 2019 Apr 13. Review.

PMID:
31009912
2.

The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.

Gallorini M, Maccallini C, Ammazzalorso A, Amoia P, De Filippis B, Fantacuzzi M, Giampietro L, Cataldi A, Amoroso R.

Int J Mol Sci. 2019 Jan 24;20(3). pii: E495. doi: 10.3390/ijms20030495.

3.

Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.

Giancristofaro A, Barbosa AJM, Ammazzalorso A, Amoia P, De Filippis B, Fantacuzzi M, Giampietro L, Maccallini C, Amoroso R.

Medchemcomm. 2018 Jul 4;9(10):1630-1638. doi: 10.1039/c8md00272j. eCollection 2018 Oct 1.

4.

Discovery of N-{3-[(ethanimidoylamino)methyl]benzyl}-l-prolinamide dihydrochloride: A new potent and selective inhibitor of the inducible nitric oxide synthase as a promising agent for the therapy of malignant glioma.

Maccallini C, Di Matteo M, Gallorini M, Montagnani M, Graziani V, Ammazzalorso A, Amoia P, De Filippis B, Di Silvestre S, Fantacuzzi M, Giampietro L, Potenza MA, Re N, Pandolfi A, Cataldi A, Amoroso R.

Eur J Med Chem. 2018 May 25;152:53-64. doi: 10.1016/j.ejmech.2018.04.027. Epub 2018 Apr 13.

PMID:
29689474

Supplemental Content

Loading ...
Support Center